Clinical Trial Detail

NCT ID NCT03316872
Title Study of Pembrolizumab and Radiotherapy in Liver Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

hepatocellular carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.